Ástralía - enska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - zinc chloride, quantity: 5.3 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - indications as at 01 jan 1991 : zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing. indications as at 01 jan 1991 : zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - cyanocobalamin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - cobalamin deficiency may exist that is unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of vitamin b12 may be insufficient in pernicious anaemia, malabsorption disorders, gastrectomy and gastrointestinal pathologies. specific indications may include: 1. pernicious anaemia as a result of in situ b12 deficiency.

Bandaríkin - enska - NLM (National Library of Medicine)

bongeo pharmaceuticals, inc. - vitamin a acetate (unii: 3le3d9d6oy) (vitamin a - unii:81g40h8b0t), beta carotene (unii: 01yae03m7j) (beta carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), levomefolate glucosamine (unii: q65pl71q1a) (levomefolate glucosamine - unii:q65pl71q1a), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37), cupric oxide (unii: v1xjq704r4) (cupric cation - unii:8cbv67279l), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - off-white to pale yellow, speckled, berry flavored, hexagon shaped chewable tablet. debossed "174" on one side and scored on the other.

Bandaríkin - enska - NLM (National Library of Medicine)

bongeo pharmaceuticals, inc. - vitamin a acetate (unii: 3le3d9d6oy) (vitamin a - unii:81g40h8b0t), beta carotene (unii: 01yae03m7j) (beta carotene - unii:01yae03m7j), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), .alpha.-tocopherol (unii: h4n855pnz1) (.alpha.-tocopherol - unii:h4n855pnz1), thiamine (unii: x66nso3n35) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine (unii: kv2jz1bi6z) (pyridoxine - unii:kv2jz1bi6z), levomefolate glucosamine (unii: q65pl71q1a) (levomefolate glucosamine - unii:q65pl71q1a), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), biotin (unii: 6so6u10h04) (biotin - unii:6so6u10h04), zinc gluconate (unii: u6wsn5sq1z) (zinc cation - unii:13s1s8sf37), cupric oxide (unii: v1xjq704r4) (cupric cation - unii:8cbv67279l), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - off-white to pale yellow, speckled, berry flavored, hexagon shaped chewable tablet. debossed "177" on one side and scored on the other.

Bandaríkin - enska - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - vusion ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. a positive fungal culture for candida albicans is not adequate evidence of candidal infection since colonization with c. albicans can result in a positive culture. the presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. vusion should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. vusion should not be used as a substitute for frequent diaper changes. the safety and efficacy of vusion have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term). the safety and efficacy of vusion have not been evaluated in incontinent adult

Bandaríkin - enska - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - miconazole nitrate (unii: vw4h1cyw1k) (miconazole - unii:7nno0d7s5m), zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z), petrolatum (unii: 4t6h12bn9u) (petrolatum - unii:4t6h12bn9u) - miconazole nitrate, zinc oxide and white petrolatum ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. a positive fungal culture for candida albicans is not adequate evidence of candidal infection since colonization with c. albicans can result in a positive culture. the presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. miconazole nitrate, zinc oxide and white petrolatum ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. miconazole nitrate, zinc oxide and white petrolatum ointment should not be used as a substitute for frequent diaper changes. the safety and efficacy of miconazole nitrate, zinc oxide and white petrolatum

Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - crestor is indicated as adjunctive therapy to diet to reduce elevated total-c, ldl-c, apob, nonhdl‑c, and triglycerides and to increase hdl‑c in adult patients with primary hyperlipidemia or mixed dyslipidemia. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. crestor is indicated as an adjunct to diet to: - reduce total-c, ldl-c and apob levels in children and adolescents 8 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: ldl-c >190 mg/dl, or >160 mg/dl along with a positive family history of premature cardiovascular disease (cvd) or two or more other cvd risk factors. - reduce ldl-c, total-c, nonhdl-c and apob in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., ldl apheresi

Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - crestor is indicated as adjunctive therapy to diet to reduce elevated total-c, ldl-c, apob, nonhdl‑c, and triglycerides and to increase hdl‑c in adult patients with primary hyperlipidemia or mixed dyslipidemia. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. crestor is indicated as an adjunct to diet to: - reduce total-c, ldl-c and apob levels in children and adolescents 8 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: ldl-c >190 mg/dl, or >160 mg/dl along with a positive family history of premature cardiovascular disease (cvd) or two or more other cvd risk factors. - reduce ldl-c, total-c, nonhdl-c and apob in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., ldl apheresi

Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - rosuvastatin calcium (unii: 83mvu38m7q) (rosuvastatin - unii:413kh5zj73) - crestor is indicated as adjunctive therapy to diet to reduce elevated total-c, ldl-c, apob, nonhdl‑c, and triglycerides and to increase hdl‑c in adult patients with primary hyperlipidemia or mixed dyslipidemia. lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate. crestor is indicated as an adjunct to diet to: - reduce total-c, ldl-c and apob levels in children and adolescents 8 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: ldl-c >190 mg/dl, or >160 mg/dl along with a positive family history of premature cardiovascular disease (cvd) or two or more other cvd risk factors. - reduce ldl-c, total-c, nonhdl-c and apob in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., ldl apheresi

Bandaríkin - enska - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - first aid antibiotic first aid to help prevent infection in - minor cuts  - scrapes  - burns